BioMarin Pharmaceutical, Inc. (BMRN)
57.18
-1.26
(-2.16%)
USD |
NASDAQ |
Oct 02, 16:00
57.30
+0.12
(+0.21%)
After-Hours: 20:00
BioMarin Pharmaceutical Enterprise Value : 14.41B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 14.41B |
| October 01, 2026 | 14.65B |
| September 30, 2026 | 14.96B |
| September 29, 2026 | 14.93B |
| September 28, 2026 | 14.85B |
| September 25, 2026 | 15.01B |
| September 24, 2026 | 15.22B |
| September 23, 2026 | 15.38B |
| September 22, 2026 | 15.61B |
| September 21, 2026 | 15.74B |
| September 18, 2026 | 15.72B |
| September 17, 2026 | 15.94B |
| September 16, 2026 | 15.87B |
| September 15, 2026 | 15.82B |
| September 14, 2026 | 16.20B |
| September 11, 2026 | 16.06B |
| September 10, 2026 | 16.02B |
| September 09, 2026 | 15.81B |
| September 08, 2026 | 15.85B |
| September 04, 2026 | 16.22B |
| September 03, 2026 | 16.20B |
| September 02, 2026 | 16.30B |
| September 01, 2026 | 15.89B |
| August 31, 2026 | 15.97B |
| August 28, 2026 | 15.86B |
| Date | Value |
|---|---|
| August 27, 2026 | 15.98B |
| August 26, 2026 | 16.04B |
| August 25, 2026 | 16.14B |
| August 24, 2026 | 15.94B |
| August 21, 2026 | 16.25B |
| August 20, 2026 | 16.44B |
| August 19, 2026 | 16.76B |
| August 18, 2026 | 16.31B |
| August 17, 2026 | 16.24B |
| August 14, 2026 | 16.38B |
| August 13, 2026 | 16.61B |
| August 12, 2026 | 16.94B |
| August 11, 2026 | 16.80B |
| August 10, 2026 | 16.67B |
| August 07, 2026 | 15.69B |
| August 06, 2026 | 15.24B |
| August 05, 2026 | 14.94B |
| August 04, 2026 | 15.10B |
| August 03, 2026 | 14.95B |
| July 31, 2026 | 14.96B |
| July 30, 2026 | 15.07B |
| July 29, 2026 | 15.22B |
| July 28, 2026 | 15.36B |
| July 27, 2026 | 15.01B |
| July 24, 2026 | 14.83B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
| Ascendis Pharma A/S | 14.55B |
| BridgeBio Pharma, Inc. | 15.82B |
| Incyte Corp. | 18.68B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 44.76M |
| Revenue (Quarterly) | 996.38M |
| Total Expenses (Quarterly) | 951.62M |
| EPS Diluted (Quarterly) | 0.2302 |
| Gross Profit Margin (Quarterly) | 72.27% |
| Profit Margin (Quarterly) | 4.49% |
| Earnings Yield | 0.65% |
| Operating Earnings Yield | 5.76% |
| Normalized Earnings Yield | 3.445 |